<?xml version='1.0' encoding='utf-8'?>
<document id="16197363"><sentence text="Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety."><entity charOffset="0-9" id="DDI-PubMed.16197363.s1.e0" text="Meloxicam" /></sentence><sentence text="The discovery of two distinct isoenzymes of COX has led to the development and clinical introduction of COX-2 inhibitors with increased selectivity onto the market" /><sentence text=" Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, and is a preferential inhibitor of COX-2, demonstrating effectiveness with anti-inflammatory, analgesic and antipyretic activity"><entity charOffset="1-10" id="DDI-PubMed.16197363.s3.e0" text="Meloxicam" /></sentence><sentence text=" Meloxicam is therapeutically utilised in the management of osteoarthritis and rheumatoid arthritis"><entity charOffset="1-10" id="DDI-PubMed.16197363.s4.e0" text="Meloxicam" /></sentence><sentence text=" Trials have examined the risk of gastrointestinal ulceration of meloxicam when compared with traditional non-specific COX-inhibiting NSAIDs with mixed results; meloxicam seems to have a greater gastrointestinal risk than the highly specific COX-2 NSAIDs"><entity charOffset="65-74" id="DDI-PubMed.16197363.s5.e0" text="meloxicam" /><entity charOffset="161-170" id="DDI-PubMed.16197363.s5.e1" text="meloxicam" /><pair ddi="false" e1="DDI-PubMed.16197363.s5.e0" e2="DDI-PubMed.16197363.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16197363.s5.e0" e2="DDI-PubMed.16197363.s5.e1" /></sentence><sentence text=" Meloxicam has a plasma half-life of approximately 20 h and is convenient for once daily administration"><entity charOffset="1-10" id="DDI-PubMed.16197363.s6.e0" text="Meloxicam" /></sentence><sentence text=" Neither moderate renal nor hepatic insufficiency significantly alters the pharmacokinetics of meloxicam in short-term studies"><entity charOffset="95-104" id="DDI-PubMed.16197363.s7.e0" text="meloxicam" /></sentence><sentence text=" Furthermore, dose adjustment is not required in the elderly" /><sentence text=" Recent drug-drug interaction studies have demonstrated that meloxicam interacts with some medications, including cholestyramine, lithium and some inhibitors of cytochrome P450 -2C9 and -3A4"><entity charOffset="61-70" id="DDI-PubMed.16197363.s9.e0" text="meloxicam" /><entity charOffset="114-128" id="DDI-PubMed.16197363.s9.e1" text="cholestyramine" /><entity charOffset="130-137" id="DDI-PubMed.16197363.s9.e2" text="lithium" /><pair ddi="false" e1="DDI-PubMed.16197363.s9.e0" e2="DDI-PubMed.16197363.s9.e0" /><pair ddi="false" e1="DDI-PubMed.16197363.s9.e0" e2="DDI-PubMed.16197363.s9.e1" /><pair ddi="false" e1="DDI-PubMed.16197363.s9.e0" e2="DDI-PubMed.16197363.s9.e2" /><pair ddi="false" e1="DDI-PubMed.16197363.s9.e1" e2="DDI-PubMed.16197363.s9.e1" /><pair ddi="false" e1="DDI-PubMed.16197363.s9.e1" e2="DDI-PubMed.16197363.s9.e2" /></sentence><sentence text=" Consequently, increased clinical vigilance should be maintained when coprescribing some medications with meloxicam"><entity charOffset="106-115" id="DDI-PubMed.16197363.s10.e0" text="meloxicam" /></sentence><sentence text=" Concentration-dependent therapeutic and toxicological effects have yet to be extensively elucidated for meloxicam"><entity charOffset="105-114" id="DDI-PubMed.16197363.s11.e0" text="meloxicam" /></sentence><sentence text=" Long-term safety in various organ systems, especially in the heart and vascular system and with concomitant drug administration, remains to be proven" /><sentence text=" The pharmacokinetics of meloxicam enables once daily application, which increases compliance compared with some shorter acting NSAIDs; however, long-term clinical data clearly demonstrating safety and efficacy advantages are lacking"><entity charOffset="25-34" id="DDI-PubMed.16197363.s13.e0" text="meloxicam" /></sentence><sentence text="" /></document>